普鲁努斯mume缓解高尿血性损伤:从网络药理学和实验模型的见解
ShaoJun Zheng1,2,3,4, Sheng Li1,2,3,5, XiaoHan Diao1,2,3,5
1College of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, China.
Biomedical chromatography : BMC
|March 5, 2025
概括
普鲁努斯姆 (Prunus mume) 提取物显示出对高尿酸水平引起的脏损伤的保护作用. 它减少了炎症和氧化应激,为脏健康提供了潜在的治疗益处.
科学领域:
- 传统中国医药 传统中国医药
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 普鲁努斯穆梅 (Prunus mume,简称PM) 是一种传统的草药,被认为具有各种健康益处.
- 新兴研究强调了PM的抗炎,抗氧化和尿酸降低特性.
- 高尿路血症可能导致严重的损伤,需要新的治疗策略.
研究的目的:
- 为了研究Prunus mume对高尿血引起的损伤的保护作用.
- 阐明潜在的机制,包括抗炎和抗氧化活性.
- 分析化学成分及其潜在的治疗作用.
主要方法:
- 网络药理学和LC-MS被用来识别PM的化学成分和活性化合物.
- 采用的超尿血模型来评估PM对脏损伤的体内影响.
- 使用HK-2细胞进行的体外研究评估了PM对氧化应激标志物 (MDA,SOD,GSH) 和炎症类细胞因子 (TNF-α,IL-6) 的影响.
- 西方涂抹分析了尿酸转运体 (URAT1,GLUT9) 和PI3K/AKT通路的调节.
主要成果:
- 在LC-MS分析中,在PM中发现了284种化合物,其中35种被预测为活性成分.
- 在高尿血症诱导的长模型中,PM对脏产生了显著的保护作用.
- 在体外,PM降低了氧化应激,降低了TNF-α和IL-6水平,并调节了URAT1和GLUT9的表达.
- PM影响了PI3K/AKT信号通路,这表明PM在细胞保护中的作用.
结论:
- 普鲁努斯·穆梅 (Prunus mume) 在缓解高尿血引起的损伤方面表现出有前途的治疗潜力.
- 它的保护作用归因于强大的抗炎和抗氧化活性.
- 粉素可以通过调节尿酸运输蛋白和调节PI3K/AKT通路来发挥其益处.
相关概念视频
01:15Model Approaches for Pharmacokinetic Data: Physiological Models
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
01:13Physiological Pharmacokinetic Models: Assumption with Protein Binding
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).